Study of SHR-A1904 for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests an experimental drug called SHR-A1904 in people with advanced colorectal cancer that has not responded to previous treatments. The goal is to see if the drug can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with colorectal cancer that has spread to other parts of the body.
- You have already tried at least two standard treatments, including chemotherapy with oxaliplatin, irinotecan, and fluoropyrimidine.
- You have at least one tumor that can be measured on a scan.
- You are generally able to take care of yourself (ECOG performance status 0 or 1).
- Your major organs (like bone marrow, liver, kidneys) are functioning well enough, as shown by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three new drugs (SHR-1701, SHR2554, and BP102) for people with metastatic colorectal cancer. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a new drug called SHR-A1904 for people with advanced neuroendocrine carcinoma that has grown after standard chemotherapy. The drug is given alone and may help shrink tumors or slow the disease.
This trial tests a new targeted drug (SHR-A1811) combined with chemotherapy and bevacizumab versus the usual therapy for advanced colorectal cancer that hasn't been treated yet. It aims to see if the new combo works better as a first treatment.
This trial is testing a new drug, SHR-A2102, either alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This study is testing a new drug, SHR-3821, to see if it can help people with advanced colorectal cancer that has stopped responding to previous treatments. The goal is to evaluate how well it works and what the side effects might be, offering a potential new option for patients who have limited alternatives.
This trial tests a new drug called SHR-A1904 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has already been treated once. It is for those whose tumors are positive for a protein called CLDN18.2.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.